Advanced Solid Tumors research hub

Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

This study looks at a new medicine called Tuvusertib for people with advanced solid tumours. It aims to understand how the body uses and gets rid of the medicine, and how much of it reaches the bloodstream when taken by mouth compared to other ways. This is an early-stage study.

A Multicenter, Open-label, Phase 2 Basket Study of MK‑7684A, a Co formation of Vibostolimab (MK‑7684) With Pembrolizumab (MK‑3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (KEYVIBE 005)

This study, called KEYVIBE 005, is testing a new combination of medicines (MK-7684A, which includes vibostolimab and pembrolizumab) for people with advanced solid tumours. Researchers want to see how well this new treatment shrinks tumours and stops them from growing, either alone or with other cancer therapies.

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers

This study is testing a new medicine, BMS-986253, alongside existing cancer treatments (Nivolumab and Ipilimumab) for advanced cancers. Doctors want to see how safe the combined medicines are and if they help shrink tumors. It's an early-stage study to gather important information.

A Phase 1/2, First-In-Human, Multi-Part, Open Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

This study is testing a new drug (DF6002) for advanced cancers, alone or with an existing drug (Nivolumab). It's looking to see if it's safe, how it moves through the body, and if it helps shrink tumors. It's an early-stage trial for people with solid tumors.

A First in Human open label study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-Tumor Activity of VVD-130850 as Single Agent and in Combination with Checkpoint Inhibition in Participants with Advanced Solid and Hematologic Tumors.

Scientists are testing a new medicine called VVD-130850 in people with advanced cancers. They want to see if it's safe, how it works in the body, and if it can help fight cancer, both on its own and with other treatments.

Phase 1/1b Multiple-Ascending Dose Study of DF6215 in Patients With Advanced Solid Tumors

This early-stage study is looking at a new medicine called DF6215 for people with advanced cancers that have spread. Researchers want to find a safe dose and see how it works in the body.

A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors

This study is looking into a new medication called TNO155 for adults who have advanced solid cancers that have spread. It’s a very early-stage study to find the best dose and check its safety. We want to see how the body handles this new medicine.

A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the body, what maximum amount can be given, how it moves into, through and out of the body, how it acts on different tumors in participants with advanced solid tumors

This study is the first time a new medicine, BAY2965501, is being tested in people. It aims to find out if it's safe, what dose works best, and how it affects the body in people with advanced solid cancers.

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

This study is testing a new medicine, HFB200301, for adults with advanced cancers. It will check if the medicine is safe and how it works, both on its own and with another cancer drug called Tislelizumab.

Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors

This study is looking for new ways to treat advanced cancers. It's testing a new medicine called PM14 given through a drip. Researchers want to find the right dose and see how it works in the body and if it helps people with advanced solid tumours.

A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults

This study is looking at a new drug, BAY 2416964, together with a common cancer treatment, pembrolizumab. It aims to see if this combination is safe, how it works in the body, and if it can help adults with advanced solid cancers. It's an early-stage study.

A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors

This early-stage study is looking at a new medicine called IK-930 for people with advanced cancers. It's the very first time this medicine is being given to people, to check if it's safe and how it works in the body.

A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab and/or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants with Locally Advanced or Metastatic Solid Tumors

This study is testing a new drug, ASP1570, on its own and with other cancer treatments for advanced solid tumours. It aims to see how safe the new drug is and how well it works to shrink tumours or stop them from growing. It's for adults aged 18 and over.

Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors

This early-stage study is testing a new unproven medicine called RP-1664 for people with advanced solid tumours that have spread. We want to check its safety, how it moves through the body, and if it shows any early signs of helping to shrink tumours. It's the first time this drug is being given to humans.

Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors

This study is testing a new combination of two medicines, PM14 and atezolizumab, for people with advanced cancers that have already been treated. Doctors want to see if it's safe, how well people tolerate it, and if it helps treat these cancers.

A first-in-human study to learn how safe the study treatment BAY2862789 is, to find the best dose, how it affects the body, what maximum amount can be given, how it moves into, through and out of the body, and how it acts on different tumors in participants with advanced solid tumors

This early-stage study is testing a new medicine called BAY2862789 for people with advanced cancers, including a type of lung cancer. Researchers want to find a safe dose and understand how the medicine works in the body and on tumours.

A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab)

This study is for people with advanced cancers that have spread. Researchers are testing a new combination of medicines (Brigimadlin with Ezabenlimab, and sometimes another drug) to see if they are safe and what dose works best.

Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors

This study is testing a new medicine called GEN1056 for people with advanced cancers that have spread. It's the first time this medicine is being given to humans, to see if it's safe and if it can help fight cancer. All adults aged 18 and over can take part.

A Study of Oral Tazemetostat in Subjects With Moderate and Severe Liver Impairment With Advanced solid tumors or hematological malignancies

This study is looking at a new medicine called tazemetostat for people with advanced cancers. It's especially for those who also have liver problems or healthy livers. We want to see how the medicine works and if it's safe when the liver isn't working as it should.

A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors

This study is testing new combinations of medicines for advanced solid cancers. It looks at how safe the treatments are and how well they shrink or control the cancer. The aim is to find better ways to treat these cancers.

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumors

This study is testing a new medicine called RP3, sometimes with another medicine called Nivolumab, for people with advanced cancers. It's the very first time these treatments are being given to humans, to see how safe they are and what effects they have.

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

This study is testing a new drug, BAY3375968, alone or with pembrolizumab, for advanced solid tumours. It aims to find a safe dose and understand how it works by boosting the immune system to fight cancer.

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

This study looks at a new drug, mRNA-4359, by itself and with other cancer drugs. It aims to see if it's safe and what side effects it might have in people with advanced solid tumours, which are cancers that have spread.

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

This study is looking for the best way to give a new cancer drug, rilvegostomig, as an injection under the skin instead of through a vein. It's for adults with advanced solid cancers who have already had standard treatments.

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

This study is testing a new medicine, INCA33890, for people with advanced or spreading solid cancers. Doctors want to see how safe the medicine is, what side effects it causes, and find the best dose to give.

TT-702 in Patients With Advanced Solid Tumours.

This study is testing a new drug, TT-702, for people with advanced cancers. We want to find a safe dose of TT-702, by itself and with another drug called darolutamide, and see how it affects tumours.

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

This study is testing a new drug, VVD-133214, for advanced solid tumours, including a type of bowel cancer. It looks at safety, how the body handles the drug, and if it can help shrink tumours. It's an early-stage study, sometimes testing the new drug with other standard treatments.

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

This study is looking into new ways to treat advanced cancers that have a specific genetic change called KRAS p.G12C. It's testing a drug called sotorasib, either by itself or with other treatments, to see how safe and effective they are for adults.

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

This study looks at new drug combinations for advanced cancers. We want to see if they're safe, how well they work, and what effects they have on the body. It involves different stages to find the best doses and see benefits.

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

This study is testing a new medicine, ZN-A-1041, for people with advanced cancers that have a specific marker called HER2. It will look at how safe and effective ZN-A-1041 is, both alone and with other usual treatments, for solid tumours including breast cancer.

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

This study is testing a new drug, BAY2965501, for advanced cancers like skin, kidney, stomach, and lung cancer. It aims to find a safe dose, how it affects the body, and if it helps shrink tumors. The drug works by boosting the body's own immune cells to fight cancer.

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

This study is testing a new medicine, WEF-001, for people with advanced cancers that have a specific genetic change called a 'KRAS mutation'. Doctors want to see if it's safe, how the body handles it, and if it could help shrink tumours.

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti_Tumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients with Advanced Solid Tumors.

This study is testing a new drug, AVZO-021, for people with advanced cancers. It's the first time it’s being given to humans, looking at how safe it is, how the body handles it, and if it can help fight the cancer.

First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors

This study is looking into a new medication called DS-1471a for people with advanced cancers. It's the very first time this drug will be given to humans, to see if it's safe and how it works in the body.

A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations

This early-stage study is looking at a new medicine called ATV-1601. It's for adults with advanced cancers, especially breast cancer, that have a specific genetic change called an AKT1 E17K mutation. The main goal is to see if the medicine is safe and how it works in people.

A Study Testing the Investigational Drug XmAb541 in people with Advanced Cancer

This study is testing a new medicine called XmAb541 for people with advanced cancer. It's an early-stage study to see how the medicine works in people for the first time, checking its safety and effects.

A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.

This study is testing a new combination of treatments for adults with certain advanced cancers, including kidney, bowel, and pancreatic cancer. It aims to find out if the new combination is safe and how well it works. This is an early-stage study.

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

This study is testing a new medicine called M7437 for people with advanced cancers that have spread. It's the very first time this medicine is being given to humans, to see if it's safe and how it works in the body. The aim is to find new ways to treat these difficult cancers.

C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors

This study is testing a new combination of treatments, including a medicine called PF-08634404, for people with advanced solid tumours. It aims to see how safe the treatments are and how well they work together against cancer.

First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

This study is the very first time a new medicine called DS3610a is being tested in people with advanced cancers. Doctors want to see if it's safe and how it works in the body. It's an early-stage study to understand this new treatment better.

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

This study is looking at a new drug, EIK1005, alone or with another approved cancer drug, Pembrolizumab. It’s for adults with certain advanced cancers to see how safe it is and how well it works. This is an early-stage study.

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Selected Advanced Solid Tumors

A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients with Selected Advanced Solid Tumors

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

A study of HFB200603 as a single agent and in combination with Tislelizumab in patients with advanced solid tumors

A Study of ZL-1218 with or without Pembrolizumab in Subjects with Advanced Solid Tumor Cancers to Find a Suitable Dose and to Test How Different Doses of these Medications can be Tolerated by the Body

A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer

A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors.

An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination with an Anti-PD1 Antibody in Patients with Advanced Solid Tumors